美国食品药品监督管理局（FDA）已授予抗体偶联药物Ifinatamab Deruxtecan优先审评资格。该药物旨在治疗既往接受过治疗、且在铂类化疗期间或之后出现疾病进展的广泛期小细胞肺癌（ES-SCLC）成人患者。
优先审评旨在加速针对严重疾病且可能提供显著治疗优势的药物的审评流程。此次授予基于一项积极的临床试验数据，显示出该疗法在此类难治患者群体中的潜力。
美国食品药品监督管理局（FDA）已授予抗体偶联药物Ifinatamab Deruxtecan优先审评资格。该药物旨在治疗既往接受过治疗、且在铂类化疗期间或之后出现疾病进展的广泛期小细胞肺癌（ES-SCLC）成人患者。
优先审评旨在加速针对严重疾病且可能提供显著治疗优势的药物的审评流程。此次授予基于一项积极的临床试验数据，显示出该疗法在此类难治患者群体中的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.